KMPH

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

Retrieved on: 
Tuesday, February 28, 2023
National Organization for Rare Disorders, Therapy, NORD, Rare, Disease, Research, Patient, Corporate Council on Africa, Idiopathic hypersomnia, KMPH, Niemann–Pick disease, Rare Disease Day, Symbolism, Pharmaceutical industry, Zebra

CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023.

Key Points: 
  • CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023.
  • A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people.
  • As a company focused on advancing therapies for rare diseases, Zevra stands with NORD and the rare disease community today and every day.
  • “We enthusiastically welcome Zevra as an important partner for our community and appreciate the symbolism of its new name inspired by the zebra – the international symbol of the rare disease community."

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

Retrieved on: 
Monday, February 27, 2023
Safety, Therapy, Quality of life, Annual, Disease, Drug development, Annual general meeting, FDA, Investment, Patient, Growth, Ageing, Corium, KMPH, History, Niemann–Pick disease, Idiopathic hypersomnia, New Drug Application, ADHD, Annual Meetings of the International Monetary Fund and the World Bank Group, Pharmaceutical industry, Shareholder, Zebra

With the re-election of these serving directors, the Zevra Board will comprise seven highly qualified individuals, five of whom are independent and each of whom is actively engaged in overseeing Zevra’s transformation into a commercially driven rare disease therapeutics company.

Key Points: 
  • With the re-election of these serving directors, the Zevra Board will comprise seven highly qualified individuals, five of whom are independent and each of whom is actively engaged in overseeing Zevra’s transformation into a commercially driven rare disease therapeutics company.
  • “Our name change and new Zevra brand are key steps in advancing our company’s focus on rare disease therapeutic research, development and commercialization,” said Matthew R. Plooster, Chairman of the Zevra Board of Directors.
  • Proxy battles can be costly and distracting, and as such, I intend to vote in favor of the Zevra slate.
  • The Zevra Board recommends that stockholders discard any proxy materials from Daniel Mangless and vote using the WHITE proxy card they will receive as part of the definitive proxy materials that will be delivered by the Company.

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

Retrieved on: 
Monday, February 27, 2023
Disease, Therapy, KMPH, Webcast, Zebra

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m.

Key Points: 
  • CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m.
  • ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.
  • The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company’s website, http://investors.zevra.com/ .
  • An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m.

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

Retrieved on: 
Friday, February 24, 2023
Speech, Glycogen storage disease, Pediatrics, Therapy, SARA, Mayo Clinic, OLE, Cerebellar ataxia, Research, Niemann–Pick disease, Standard of care, FDA, Data analysis, DB, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, KMPH, Medical genetics, Cognition, New Drug Application, Death, Assessment, Neurology, Food, Pharmaceutical industry, Zebra, Ataxia, EU, NPC

CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a treatment for Niemann-Pick disease type C (NPC), is being featured in two poster presentations during the 19th Annual WORLDSymposium™ 2023, the annual research conference dedicated to lysosomal diseases being held February 22-26, 2023 in Orlando, Florida, USA.

Key Points: 
  • Research presented at WORLDSymposium™ 2023 included an interim analysis from the ongoing four-year open-label extension of the Phase 2/3 clinical trial of arimoclomol.
  • Results from this analysis, based on up to four years of continuous treatment, suggest that arimoclomol may reduce the long-term progression of NPC.
  • “We are pleased to share this important research of arimoclomol at WORLDSymposium™ 2023, which expands our understanding of the potential for arimoclomol to decrease the long-term progression of NPC,” said Travis C. Mickle, Ph.D., President of Zevra.
  • As presented at WORLDSymposium™ 2023, results from the data analysis indicated that long-term progression of NPC may be reduced in patients treated with arimoclomol.

Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

Retrieved on: 
Thursday, February 23, 2023
Therapy, Zebra, Lipid, Disease, Cell, Research, Abstract, NDA, KMPH, Niemann–Pick disease, New Drug Application, Arimoclomol, NPC, Pharmaceutical industry

CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLDSymposium™ 2023, an annual research conference dedicated to lysosomal diseases.

Key Points: 
  • CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLDSymposium™ 2023, an annual research conference dedicated to lysosomal diseases.
  • WORLDSymposium 2023 is held February 22-26, 2023, in Orlando, Florida.
  • Arimoclomol has been studied in ten Phase 1, four Phase 2, and three pivotal Phase 2/3 trials.
  • Zevra is currently preparing an updated New Drug Application (NDA) for arimoclomol as a treatment for NPC, which the Company expects to file as early as the third quarter of 2023.

KemPharm Announces Corporate Name Change to Zevra Therapeutics

Retrieved on: 
Wednesday, February 22, 2023
Therapy, Sleep disorder, Rare, Disease, Bone marrow, Drug development, Arimoclomol, Acquisition, Brain, Research, FDA, Patient, Liver, KMPH, Niemann–Pick disease, Idiopathic hypersomnia, Narcolepsy, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Caregiver, Food, Spleen, Rare disease, NPC, Pharmaceutical industry, Zebra, IH

CELEBRATION, Fla., Feb. 22, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (“KemPharm,” or the “Company”), announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”). This name change reflects the Company’s intensified focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options. In conjunction with the name change, the Company will begin trading under the new ticker symbol “ZVRA” on The Nasdaq Global Market on or about March 1, 2023.

Key Points: 
  • This name change reflects the Company’s intensified focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options.
  • In conjunction with the name change, the Company will begin trading under the new ticker symbol “ZVRA” on The Nasdaq Global Market on or about March 1, 2023.
  • “The adoption of the name Zevra, the Greek word for zebra, is an important step in our journey to become a leading rare disease company since the zebra is the recognized symbol of the rare disease community around the world,” said Richard W. Pascoe, Chief Executive Officer of Zevra.
  • “The launch of the Zevra brand today marks the next key step in our evolution into a commercially-focused rare disease therapeutics company.

Sinclair Broadcast Group Names Susan Connor Vice President and General Manager of KMPH and KFRE in Fresno, CA

Retrieved on: 
Tuesday, February 21, 2023
Entertainment, Communications, Other Entertainment, General Entertainment, TV and Radio, Media, KFRE, Wichita State University, WHBQ, CW, KMPH, OR, SBGI, FOX, KIRO, CBS, KTVL, Sinclair Broadcast Group, Management, Broadcasting, Advertising

Sinclair Broadcast Group, Inc. (Nasdaq: SBGI) today announced Susan Connor has been named VP/General Manager of KMPH (FOX) and KFRE (CW) in Fresno/Visalia, CA.

Key Points: 
  • Sinclair Broadcast Group, Inc. (Nasdaq: SBGI) today announced Susan Connor has been named VP/General Manager of KMPH (FOX) and KFRE (CW) in Fresno/Visalia, CA.
  • Connor was most recently VP/GM of KTVL (CBS) in Medford, OR, a position she has held since joining Sinclair in 2019.
  • In making the announcement, Rob Weisbord, Chief Operating Officer and President of Broadcast, said, “Susan has a track record of growing stations, and we saw great success under her leadership at KTVL in Medford.
  • “After three years as the VP/General Manager in Medford, OR I am honored and humbled to be promoted within the company to our great group of stations in Fresno, CA,” said Connor.

KemPharm Enhances Senior Management Team

Retrieved on: 
Tuesday, January 31, 2023
Northwestern University, B.A, Marketing, Disease, Gastroenterology, Catholic University of America, CNS, Vanderbilt University, AbbVie, KMPH, LLP, Niemann–Pick disease, Glycogen storage disease, Therapy, Loeb, Catholic higher education, Research, Neurodegeneration, Central nervous system, Medical Affairs Bureau, Patient, EAP, Legal Affairs, NPC, Growth, Johnson & Johnson, Knowledge, Molecular biology, Doctor of Philosophy, Pharmaceutical industry, Medical device

CELEBRATION, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs. Both positions are newly created at KemPharm and continue a series of enhancements to the Company’s leadership to support its transformation into a leading rare disease company.   

Key Points: 
  • Both positions are newly created at KemPharm and continue a series of enhancements to the Company’s leadership to support its transformation into a leading rare disease company.
  • “Dan and Abbi have been brought into KemPharm to provide this expertise, and we are excited to benefit from their knowledge and experience working with companies that have undergone similar growth.
  • Additionally, he built Orphazyme’s field medical team and led planning and execution of external engagement and collaboration, evidence generation, and scientific communications.
  • As Senior Corporate Counsel, Ms. Maher served on a five-member legal team where she led the drafting, reviewing, negotiation and execution of Cytel’s global vendor and customer agreements.

KemPharm Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 24, 2023
Disease, Narcolepsy, Idiopathic hypersomnia, IH, Food, Safety, Somnolence, Arimoclomol, CNS, Cognition, KMPH, Acquisition, Pediatrics, Neurodegeneration, Niemann–Pick disease, Special access program, Glycogen storage disease, Therapy, Death, European Medicines Agency, Lipid, NDA, Child development stages, New Drug Application, Central nervous system, Letter, SDX, Learning, Patient, RICH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Methylphenidate, Interim, NPC, Investment, Growth, Speech, EAPS, Cell, Degenerative disease, Brain, Pharmaceutical industry, Management, Risk management, Shareholder

CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.

Key Points: 
  • CELEBRATION, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.
  • KemPharm is a company founded on solid science and this will continue to be a pillar upon which we stand.
  • However, solid science alone will not be enough to propel KemPharm into its next stage of growth and create the value that our shareholders deserve.
  • Our move to rare diseases is an opportunity to build upon what is good at KemPharm and make it great.

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

Retrieved on: 
Wednesday, January 18, 2023
Disease, Caregiver, MFA, CNS, Sleep disorder, IH, Safety, Knowledge, Idiopathic hypersomnia, Partnership, Central nervous system, KMPH, Therapy, Patient, Glycogen storage disease, Hypersomnia, Sleep, Neurodegeneration, Pharmaceutical industry

IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

Key Points: 
  • IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.
  • KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.
  • “IH is a rare sleep disorder for which few treatment options exist.
  • “Support from sponsors like KemPharm are key to our efforts to advocate for and support those dealing with debilitating sleep disorders.”